Torgrim Tandstad

Torgrim Tandstad

Auto-generated profile, based on publicly available information

Torgrim Tandstad

Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; The Cancer Clinic, St. Olavs University Hospital, Trondheim, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Acta Oncologica
Verified
Journal Article
Closed access
JKJarle Karlsen
Jarle Karlsen
TTTorgrim Tandstad
Torgrim Tandstad
PSPiotr Sowa
Piotr Sowa
ØSØyvind Salvesen
Øyvind Salvesen
JSJo S. Stenehjem
Jo S. Stenehjem
RRRandi Johansen Reidunsdatter
Randi Johansen Reidunsdatter
Radiation pneumonitis (RP) and radiation fibrosis (RF) are common side effects after breast cancer (BC) radiotherapy (RT). However, there is a great variation in the frequency of RP and RF. This st...

18 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ØKØivind Kvammen
Øivind Kvammen
TMTor Åge Myklebust
Tor Åge Myklebust
ASArne Solberg
Arne Solberg
BMBjørn Møller
Bjørn Møller
OKOlbjørn Harald Klepp
Olbjørn Harald Klepp
TTTorgrim Tandstad
Torgrim Tandstad
Testicular germ cell tumor (TGCT) patients and survivors have excess mortality compared to the general male population, but relative survival (RS) has been scarcely studied. We investigated causes of excess mortality and their impact on RS among men diagnosed with TGCT in Norway, 1953–2015. Using registry data (n = 9541), standardized mortality ratios (SMRs) and RS were calculated. By December 31st, 2015, 816 testicular cancer (TC) and 1508 non-TC deaths had occurred (non-TC SMR: 1.36). Within five years of TGCT diagnosis, 80% were TC deaths. Non-TC second cancer (SC) caused 65% of excess non-TC deaths, of which 34% from gastric, pancreatic or bladder cancer. SC SMRs remained elevated ≥26 years of follow-up. In localized TGCT diagnosed >1979, SC SMRs were only elevated after seminoma. Cardiovascular disease caused 9% and other causes 26% of excess non-TC deaths, of which 58% from gastrointestinal and genitourinary disorders. RS continuously declined with follow-up. TGCT patients diagnosed >1989 had superior five-year TC-specific RS (98.3%), lower non-TC SMR (1.21), but elevated SMRs for several SCs, infections, Alzheimer’s disease, genitourinary disease and suicide. A limitation was lack of individual treatment data. RS declines mainly from TC deaths <5 years after TGCT diagnosis. Later, excess SC mortality becomes particularly important, reducing RS even ≥26 years. Radiotherapy; standard adjuvant seminoma treatment 1980–2007, is likely an important contributor, as are chemotherapy and possibly innate susceptibilities. Vigilant long-term follow-up, including psychosocial aspects, is important. Further research should focus on identifying survivor risk groups and optimizing treatment.

1 November 2024 in Journal of Urology
Verified
Journal Article
Open access
ATAnna Thor
Anna Thor
MMMette Pernille Myklebust
Mette Pernille Myklebust
ABAnna Grenabo Bergdahl
Anna Grenabo Bergdahl
PLPer Olof Lundgren
Per Olof Lundgren
Viktor SkokicViktor Skokic
Viktor Skokic
AKAnders Urospeed 2 Kjellman
Anders Urospeed 2 Kjellman
The SWENOTECA-MIR prospective multicenter study aims to assess the clinical value of miR-371a-3p as a novel marker in metastatic germ cell tumor patients undergoing retroperitoneal lymph node dissection (RPLND), to predict the presence of viable residual tumor. A total of 114 patients (86 nonseminomas, 28 seminomas) who underwent surgery for presumed metastatic disease pre-chemotherapy (primary RPLND), and post-chemotherapy RPLND were included. The expression of miR-371a-3p was evaluated using RT-digital droplet PCR before and after RPLND. Pre- and post-operative miR-371a-3p levels were statistically compared, and optimism-corrected performance calculations compared with conventional serum tumor markers. Associations were evaluated by logistic regression. Patients who underwent primary RPLND were categorized into seminoma and nonseminoma groups. Among the seminoma patients (n = 24) undergoing primary RPLND, all had normal conventional markers. Six patients received adjuvant treatment before surgery. miR-371a-3p exhibited a sensitivity of 74%, specificity of 100%, PPV of 100% and NPV of 21% for viable tumor. The levels of miR-371a-3p significantly decreased after surgery. In the nonseminoma group (n = 18) treated with primary RPLND, 22% had elevated conventional markers, and 3 had received prior adjuvant treatment. miR-371a-3p showed a sensitivity of 34%, specificity of 88%, PPV of 67% and NPV of 62% for the primary nonseminoma patients. No association was observed between stage or prior adjuvant treatment, and the outcome of the miR-test. In the post-chemotherapy group (n = 72), the miR-371a-3p sensitivity was 9%, reducing to 0 when excluding patients with seminoma (n = 4). Teratomas and benign histology were essentially negative. Our study highlights miR-371a-3p as a fairly sensitive and highly specific marker for pre-chemotherapy seminomas, outperforming conventional markers. However, in pre-chemotherapy non-seminomas as well as in post-chemotherapy patients, we observed low sensitivity and no significant differences in miR-371a-3p levels before and after surgery, suggesting limited utility for miR-371a-3p in this context.

13 April 2026 in Scandinavian Journal of Urology
Verified
Journal Article
Open access
ATAnna Thor
Anna Thor
ABAnna Grenabo Bergdahl
Anna Grenabo Bergdahl
AAArmin Abniki
Armin Abniki
AGAxel Gerdtsson
Axel Gerdtsson
IGIngrid Glimelius
Ingrid Glimelius
PLPer Olof Lundgren
Per Olof Lundgren
Objective: Retroperitoneal lymph node dissection (RPLND) for testicular germ cell cancer is a complex procedure associated with postoperative complications and long-term morbidity, best performed by experienced surgeons at high-volume centers. This study evaluates surgical outcomes of RPLND in a centralized population-based cohort. Methods: This is a retrospective analysis of a prospective multicenter cohort of all RPLNDs in Sweden between 2018 and 2022. 217 patients (175 nonseminomas and 42 seminomas) underwent unilateral or bilateral primary RPLND or post-chemotherapy RPLND. Primary outcomes were complications, loss of ejaculation, and histopathology. Results: Intraoperative complications occurred in 8% of unilateral and 0% of bilateral templates in primary RPLND, and in 0 and 8% in post-chemotherapy RPLND, most commonly renal injury. Postoperative complications rate was significantly higher with bilateral templates in post-chemotherapy RPLND (49% vs 18%, p < 0.01). Clavien-Dindo ≥ IIIb complications occurred in 2 (primary) and 3% (post-chemotherapy), respectively. Loss of ejaculation was numerically more common after bilateral templates (primary: 60% vs 31%, p = 0.07; post-chemotherapy: 53% vs 38%, p = 0.09). Viable cancer was found in 95% of seminomas and 52% of nonseminomas for primary RPLND and in nonseminoma post-chemotherapy RPLND, 11% viable cancer, 50% teratoma, and 39% benign nodes. Robotic surgery did not increase complications or loss of ejaculation. Conclusions: RPLND demonstrated low complication rates and rare serious events. Bilateral templates were associated with increased loss of ejaculation. Robotic surgery was safe, and prior chemotherapy did not preclude laparoscopy. Post-chemotherapy RPLND showed more teratoma and viable cancer, and fewer benign findings than previously reported.

29 October 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
MKMaja Kulosman
Maja Kulosman
HEHarald Engan
Harald Engan
UFUnn Merete Fagerli
Unn Merete Fagerli
KRKristin Valborg Reinertsen
Kristin Valborg Reinertsen
KSKari Sand
Kari Sand
TTTorgrim Tandstad
Torgrim Tandstad
Background: Due to advances in cancer diagnostics and treatments, life expectancy after cancer and the number of cancer survivors are increasing. Symptoms and late effects frequently occur in cancer survivors, with a negative impact on functioning and participation in society. Digital health tools might be helpful to systematically assess symptom burden of late effects and rehabilitation needs. Objective: This paper describes the objectives, design, and current status of the Cancer Rehabilitation Screening (CaReScreen) project. The aims are (1) to report the completed development phase of the digital health tool CaReScreen, comprising the exploratory work, the establishment of the interdisciplinary team, the selection of the assessment instrument, and the development of the initial prototype, and (2) to define the objectives, design, and timelines of the ongoing validation of the scoring manual and of the planned large-scale feasibility study. Methods: Development followed an iterative, qualitative, and participatory design approach guided by established frameworks for digital health development. It was informed by exploratory qualitative work comprising 40 interviews (9 group and 31 individual) involving 72 informants across Norway, which identified systematic assessment of late effects and navigation of rehabilitation services as the primary unmet needs in cancer survivorship follow-up. A 105-item patient-reported outcome measure (European Organization for Research and Treatment of Cancer [EORTC] QLQ-SURV100, supplemented with 5 EORTC QLQ-C30 items) was selected as the main assessment instrument. This paper reports the completed development phase; the ongoing validation study and the planned feasibility study are described in terms of objectives, design, and timelines, but their results are not reported here. Results: An initial prototype was developed with health care professionals and cancer survivors as intended end users. It consists of a digital report that identifies and graphically visualizes a panoramic view of multidimensional needs, based on a traffic light scoring system: green indicates low symptom burden and high functioning, yellow moderate symptom burden and moderate functioning, and red high symptom burden and low functioning. The project is funded for the period 2022 to 2028. The development phase is completed, as well as early prototype usability and usefulness testing. Validation of the scoring manual is ongoing, with 800 participants included to date and reporting expected in spring 2027. A large-scale feasibility study is planned to commence in 2027. Conclusions: The CaReScreen interdisciplinary team has developed an initial digital health tool prototype with the main aim of enabling systematic assessment of late effects, functioning, and unmet rehabilitation needs in cancer survivors. The prototype now proceeds to validation and feasibility testing, which will determine its clinical utility and support regulatory approval under the European Medical Device Regulation.

26 January 2026 in Journal of Public Health Research
Verified
Journal Article
Open access
RNRoy A. Nielsen
Roy A. Nielsen
EAEliva Atieno Ambugo
Eliva Atieno Ambugo
STSteffen Torp
Steffen Torp
TTTorgrim Tandstad
Torgrim Tandstad
GSGuro Birgitte Stene
Guro Birgitte Stene
HEHarald Engan
Harald Engan
Background: Breast cancer and its treatment may contribute to an increased risk of unemployment, influenced by both disease-related factors and socioeconomic determinant. Few longitudinal studies have examined employment outcomes among women diagnosed with cancer. This retrospective study investigated long-term employment among breast cancer survivors (BCS) and assessed disease specific and socioeconomic factors associated with employment. Design and methods: Registry-based data included working age BCS in Norway 2004–2008 alive at 6 years follow-up ( N = 3560). The employment status on each BCS was compared to two matched non-cancer controls ( N = 7081) by means of logistic regression analyses with marginal effects. Separate analyses by employment status at the time of diagnosis were conducted. Results: Among BCS employed at diagnosis, 73.7%, 71.5% and 71.8% of BCS were in employment at 1, 2 and 6 years after diagnosis, respectively. BCS employed at diagnosis had significantly lower probability of being employed at all follow-up time points, compared to controls. BCS outside employment at the time of diagnosis experienced lower probability of employment compared to controls. BCS with secondary or higher education had higher probability of employment compared to BCS with basic education, and BCS living in families with children were more likely to enter employment during follow-up compared to BCS without children. Conclusions: BCS employed at diagnosis had a subsequent risk of unemployment, and BCS not employed at diagnosis had lower probability of entering employment. Additional risk factors are high age, low education, and being single without children. Significance for public health: The risk of unemployment after a breast cancer diagnosis was increased. Job loss is costly economically and socially, both for individuals and for society. Early focus on employment particularly among employees with low education and with little family support may alleviate this problem.